Larimar Therapeutics Announces Positive Data from Ongoing Long-term Open Label Study and Updates to Nomlabofusp Program for Friedreich's Ataxia

Stock Information for Larimar Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.